China Medical & HealthCare Group (HKSE:00383) Debt-to-EBITDA

: 7.41 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

China Medical & HealthCare Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$316 Mil. China Medical & HealthCare Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$483 Mil. China Medical & HealthCare Group's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$108 Mil. China Medical & HealthCare Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 7.41.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for China Medical & HealthCare Group's Debt-to-EBITDA or its related term are showing as below:

HKSE:00383' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5 Med: 11.56 Max: 22.65
Current: 9.6

During the past 13 years, the highest Debt-to-EBITDA Ratio of China Medical & HealthCare Group was 22.65. The lowest was -5.00. And the median was 11.56.

HKSE:00383's Debt-to-EBITDA is ranked worse than
88.78% of 419 companies
in the Healthcare Providers & Services industry
Industry Median: 2.57 vs HKSE:00383: 9.60

China Medical & HealthCare Group Debt-to-EBITDA Historical Data

The historical data trend for China Medical & HealthCare Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Medical & HealthCare Group Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

22.65

13.96

18.58

21.04

4.40

China Medical & HealthCare Group Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-21.67	-64.03	-9.66	13.62	7.41

Competitive Comparison

For the Medical Care Facilities subindustry, China Medical & HealthCare Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Medical & HealthCare Group Debt-to-EBITDA Distribution

For the Healthcare Providers & Services industry and Healthcare sector, China Medical & HealthCare Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China Medical & HealthCare Group's Debt-to-EBITDA falls into.

China Medical & HealthCare Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

China Medical & HealthCare Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(315.95	+	482.682)	/	181.429
	=	4.40

China Medical & HealthCare Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(315.95	+	482.682)	/	107.778
	=	7.41

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

China Medical & HealthCare Group (HKSE:00383) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

China Medical & HealthCare Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of China Medical & HealthCare Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

China Medical & HealthCare Group (HKSE:00383) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » China Medical & HealthCare Group Ltd (HKSE:00383) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

COLRF:USA SMI:Germany

Address

333 Lockhart Road, 47th Floor, United Asia Finance Centre, Wanchai, Hong Kong, HKG

Website

http://www.cmhg.com.hk

China Medical & HealthCare Group Ltd is a healthcare company operating hospitals. Its main focus is on the investment, management, and operations of healthcare and hospital businesses, eldercare businesses, trading of medical equipment and related supplies, property investment and development, securities trading and investments, provision of financial services, and strategic investment. It operates through the following business segments: Healthcare, Eldercare; Property development; Property investment; Financial services; and Securities trading and investments. The firm generates the majority of revenue from the Healthcare segment that is engaged in the operations of hospitals in the PRC.

China Medical & HealthCare Group (HKSE:00383) Headlines

No Headlines